Molecular changes driving low-grade serous ovarian cancer and implications for treatment
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Low-grade serous ovarian cancer is a distinct disease requiring new treatments. Understanding its unique molecular drivers, like MAPK pathway mutations, is key to developing effective targeted therapies beyond current chemotherapy options.
Area Of Science
- Gynecologic Oncology
- Molecular Pathology
- Translational Medicine
Background
- Low-grade serous ovarian cancer (LGSC) is now recognized as distinct from high-grade serous ovarian cancer.
- LGSC often presents at advanced stages with frequent recurrence and resistance to standard chemotherapy.
- Unique clinical and molecular behaviors necessitate novel therapeutic strategies.
Purpose Of The Study
- To review the current understanding of LGSC's clinical, pathological, and molecular features.
- To identify potential therapeutic targets and emerging research avenues for LGSC.
- To highlight the need for targeted therapies due to chemotherapy resistance.
Main Methods
- Literature review of clinical and molecular data on LGSC.
- Analysis of known molecular drivers including hormone receptors and MAPK pathway mutations.
- Examination of emerging therapeutic strategies targeting specific mutations.
Main Results
- Key molecular drivers include hormone receptor expression and MAPK pathway alterations (KRAS, BRAF, NRAS, NF1/2, EIF1AX, ERBB2).
- CDKN2A mutations suggest potential efficacy of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors.
- Other mutations (USP9X, ARID1A, PIK3CA) are present in a subset of tumors, but lack targeted therapies.
Conclusions
- LGSC requires tailored therapeutic approaches due to its distinct biology and resistance to conventional treatments.
- Targeting hormone receptors and the MAPK pathway, along with exploring CDK4/6 inhibitors, shows promise.
- Further research into LGSC's molecular landscape is crucial for developing effective, targeted therapies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...